Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer

Abstract Background The efficacy difference between the second‐ and third‐generation of anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs) after crizotinib failure in advanced ALK‐positive non–small cell lung cancer (NSCLC) has not been clarified. This study evaluates the efficacy of d...

Full description

Bibliographic Details
Main Authors: Xiya Ma, Shaoxing Yang, Kun Zhang, Jing Xu, Panpan Lv, Hongjun Gao, Haifeng Qin, Hong Wang, Xiaoqing Liu
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Thoracic Cancer
Subjects:
anaplastic lymphoma kinase
crizotinib
non–small cell lung cancer
progression
sequential
Online Access:https://doi.org/10.1111/1759-7714.14455

Internet

https://doi.org/10.1111/1759-7714.14455

Similar Items